
FDA declines to approve Capricor’s deramiocel for the treatment of Duchenne
Despite recognition of the tremendous unmet medical need in Duchenne muscular dystrophy, the FDA has decided that the evidence is not sufficient to approve Capricor’s deramiocel for the treatment of […]








